In-vitro Spinal Model for Drug Distribution Analysis

The patent creates a physical replica model of the human spinal canal and cord using transparent materials that accurately reproduce the anatomical geometry and tissue properties. This copy allows researchers to study drug distribution patterns in a controlled setting that mimics human physiology, enabling prediction of in-vivo drug behavior without direct measurement in human patients.

The patent introduces marker particles or contrast agents as intermediaries to track drug distribution through the cerebrospinal fluid. These markers serve as visible proxies that allow researchers to observe and measure drug transport mechanisms, convection patterns, and diffusion rates that would otherwise be impossible to detect in the transparent CSF medium.

The patent divides the spinal canal model into multiple segmented regions along its length, with separate access ports or sampling chambers at each segment. This segmentation allows independent measurement of drug concentration at different vertebral levels and anatomical locations, providing comprehensive spatial distribution data without requiring invasive deep needle insertion into the actual spinal cord.

The physical model replicates the entire spinal canal anatomy with external access points, allowing researchers to measure drug distribution at any location along the cord without penetrating the actual spinal cord or risking damage to neural tissue. The model serves as a safe surrogate for invasive human sampling.

The patent uses the transparent model itself as the imaging medium, eliminating the need for potentially toxic markers in human patients. Researchers can directly observe drug distribution in the transparent CSF-filled model using non-invasive optical methods, obtaining accurate distribution data without exposing the actual spinal cord to neurotoxic contrast agents.

The patent employs safe, biocompatible marker particles or fluorescent tracers with known safety profiles in the animal model studies, serving as intermediaries that allow visualization of drug transport without the neurotoxicity concerns associated with markers approved for human use. This intermediary approach enables precise measurement while minimizing harm.

The patent creates an accurate anatomical copy of the human spinal canal and cord using transparent materials that precisely reproduce human vertebral geometry, canal shape, and tissue dimensions. This human-specific model eliminates the anatomical discrepancies inherent in animal models, providing reliable predictive data for human drug distribution while maintaining the research efficiency of in-vitro experimentation.

The patent systematically varies physical parameters such as CSF flow rate, drug concentration, infusion pressure, and model temperature to simulate different physiological conditions and pathological states. This parameter control allows comprehensive study of drug distribution under multiple scenarios in the human-anatomical model, providing robust predictive accuracy without requiring multiple animal species.